BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

HealthHORIZON-RIAID: 101057442
EC Contribution
€225,615
Consortium Size
29 orgs
Start Year
2022
Summary

REMEDi4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDi4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDi4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases.The REMEDi4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach. Working closely together with research funders and the patient community, REMEDi4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDi4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into the market, through its complete value chain and consensus-based policy development mission.

Consortium (29)

🇳🇱 EATRIS ERICNL
coordinator
🇧🇪 ANTIKANKERFONDS - FONDS ANTICANCER-ANTICANCER FUNDBE
partner
🇬🇧 BEACON: FOR RARE DISEASES LTDGB
partner
🇩🇪 BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTEDE
partner
🇪🇸 CHEMOTARGETS SLES
partner
🇮🇹 DOMPE FARMACEUTICI SPAIT
partner
🇫🇷 ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORKFR
partner
🇫🇷 EURORDIS - RARE DISEASES EUROPEFR
partner
🇩🇪 FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EVDE
partner
🇪🇸 FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBREES
partner
🇪🇸 FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJALES
partner
🇫🇮 HELSINGIN YLIOPISTOFI
partner
🇮🇹 ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRIIT
partner
🇮🇹 ISTITUTO NAZIONALE TUMORI Fondazione PascaleIT
partner
🇮🇹 ISTITUTO ORTOPEDICO RIZZOLIIT
partner
🇸🇪 KAROLINSKA INSTITUTETSE
partner
🇬🇧 LIFEARCGB
partner
🇧🇪 MEDICINES FOR EUROPEBE
partner
🇪🇸 SERVICIO MADRILENO DE SALUDES
partner
🇭🇺 SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAGHU
partner
🇪🇸 TEAMIT INSTITUTE S LES
partner
🇪🇸 TEAMIT RESEARCH SLES
partner
🇬🇧 THE UNIVERSITY OF SHEFFIELDGB
partner
🇩🇪 UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTSDE
partner
🇬🇧 UNIVERSITY COLLEGE LONDONGB
partner
🇬🇧 UNIVERSITY OF HULLGB
partner
🇸🇮 UNIVERZA V LJUBLJANISI
partner
🇸🇪 UPPSALA UNIVERSITETSE
partner
🇳🇱 ZORGONDERZOEK NEDERLAND ZONNL
partner

Project Results (28)

Source: CORDIS, the EU research results database.

Publications (17)
REMEDi4ALL - Standard Operating Guideline - Fair Data Assessment
Zenodo· 2025DOI
Gadiya, Yojana; Zaliani, Andrea
Artificial intelligence for high content imaging in drug discovery
Current Opinion in Structural Biology· 2024DOI
Jordi Carreras-Puigvert; Ola Spjuth
Attention-based approach to predict drug-target interactions across seven target superfamilies
Bioinformatics· 2024DOI
Aron Schulman; Juho Rousu; Tero Aittokallio; Ziaurrehman Tanoli
Cell Painting: a decade of discovery and innovation in cellular imaging
Nature Methods· 2024DOI
Seal, Srijit; Trapotsi, Maria-Anna; Spjuth, Ola; Singh, Shantanu; Carreras-Puigvert, Jordi; Greene, Nigel; Bender, Andreas; Carpenter, Anne E
Drug repurposing for rare: progress and opportunities for the rare disease community
Frontiers in Medicine· 2024DOI
Anneliene Hechtelt Jonker; Anneliene Hechtelt Jonker; Daniel O’Connor; Daniel O’Connor; Maria Cavaller-Bellaubi; Maria Cavaller-Bellaubi; Christine Fetro; Christine Fetro; Maria Gogou; Maria Gogou; Peter A. C. ’T Hoen; Peter A. C. ’T Hoen; Martin de Kort; Martin de Kort; Heather Stone; Heather Stone; Nivedita Valentine; Nivedita Valentine; Anna Maria Gerdina Pasmooij; Anna Maria Gerdina Pasmooij
Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?
Frontiers in Medicine· 2024DOI
Claudia Fuchs; Peter A. C. ‘t Hoen; Annelieke R. Müller; Annelieke R. Müller; Annelieke R. Müller; Friederike Ehrhart; Clara D. M. Van Karnebeek; Clara D. M. Van Karnebeek; Clara D. M. Van Karnebeek
Exploring SureChEMBL from a drug discovery perspective
Nature Scientific Data· 2024DOI
Yojana Gadiya; Simran Shetty; Martin Hofmann-Apitius; Philip Gribbon; Andrea Zaliani
From pixels to phenotypes: Integrating image-based profiling with cell health data as BioMorph features improves interpretability
Molecular Biology of the Cell· 2024DOI
Srijit Seal; Jordi Carreras-Puigvert; Shantanu Singh; Anne E. Carpenter; Ola Spjuth; Andreas Bender
HPR155 Drug Repurposing: Policy Barriers to Using Existing Pharmaceuticals in New Indications: Results of a Systematic Literature Review
Value in Health· 2024DOI
Z Petykó, D Hosszú, M Csanádi, GD Obeng, D Ameyaw, K Gyöngyösi, HG van der Meer, P Pantziarka, Z Kalo, A Inotai
Improved Detection of Drug-Induced Liver Injury by Integrating Predicted<i>in vivo</i>and<i>in vitro</i>Data
Chemical Research in Toxicology· 2024DOI
Srijit Seal; Dominic P. Williams; Layla Hosseini-Gerami; Manas Mahale; Anne E. Carpenter; Ola Spjuth; Andreas Bender
Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank
Journal of Chemical Information and Modeling· 2024DOI
Srijit Seal; Ola Spjuth; Layla Hosseini-Gerami; Miguel García-Ortegón; Shantanu Singh; Andreas Bender; Anne E. Carpenter
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia
Cell Reports Medicine· 2024DOI
Adnan Awad, Shady; Dufva, Olli; Klievink, Jay; Karjalainen, Ella; Ianevski, Aleksandr; Pietarinen, Paavo; Kim, Daehong; Potdar, Swapnil; Wolf, Maija; Lotfi, Kourosh; Aittokallio, Tero; Wennerberg, Krister; Porkka, Kimmo; Mustjoki, Satu
Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta
Calcified Tissue International· 2024DOI
Paul Arundel; Nick Bishop
Nature Communications
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones· 2024DOI
Aleksandr Ianevski; Kristen Nader; Kyriaki Driva; Wojciech Senkowski; Daria Bulanova; Lidia Moyano-Galceran; Tanja Ruokoranta; Heikki Kuusanmäki; Nemo Ikonen; Philipp Sergeev; Markus Vähä-Koskela; Anil K. Giri; Anna Vähärautio; Mika Kontro; Kimmo Porkka; Esa Pitkänen; Caroline A. Heckman; Krister Wennerberg; Tero Aittokallio
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol
BMC Cancer· 2024DOI
Alfredo Budillon, Alessandra Leone, Eugenia Passaro, Lucrezia Silvestro, Francesca Foschini, Federica Iannelli, Maria Serena Roca, Marina Macchini, Francesca Bruzzese, Maria Laura Garcia Bermejo, Mercedes Rodriguez Garrote, Giampaolo Tortora, Michele Mile
RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies
Briefings in Bioinformatics· 2024DOI
Aleksandr Ianevski; Aleksandr Kushnir; Kristen Nader; Mitro Miihkinen; Henri Xhaard; Tero Aittokallio; Ziaurrehman Tanoli
Robust scoring of selective drug responses for patient-tailored therapy selection
Nature Protocols· 2023DOI
Yingjia Chen; Liye He; Aleksandr Ianevski; Pilar Ayuda-Durán; Swapnil Potdar; Jani Saarela; Juho J. Miettinen; Sari Kytölä; Susanna Miettinen; Mikko Manninen; Caroline A. Heckman; Jorrit M. Enserink; Krister Wennerberg; Tero Aittokallio
Deliverables (10)
Other Results (1)
Periodic Reporting for period 2 - REMEDi4ALL (BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL)